Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIM AIM ImmunoTech	$2.48 -1.2%	$6.94	$2.33 ▼ $39.95	$1.90M	0.88	66,615 shs	22,999 shs
NKGN NKGen Biotech	$0.13	$0.23	$0.10 ▼ $0.96	$5.96M	1.19	1.63 million shs	190 shs
SRNE Sorrento Therapeutics	$0.00 +118.2%	$0.00	$0.00 ▼ $0.02	$2.65M	0.85	122,286 shs	155,095 shs
UPTD TradeUP Acquisition	$0.92 +0.1%	$1.51	$6.88 ▼ $33.00	$2.00M	0.12	270,115 shs	6,883 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIM AIM ImmunoTech	+6.36%	-4.56%	-72.86%	-72.54%	-91.90%
NKGN NKGen Biotech	0.00%	-5.36%	-44.79%	-47.02%	-84.59%
SRNE Sorrento Therapeutics	0.00%	+46.67%	+57.14%	-67.16%	-75.56%
UPTD TradeUP Acquisition	+1.04%	+6.30%	+7.77%	-6.17%	-34.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIM AIM ImmunoTech	1.3686 of 5 stars	3.5	0.0	0.0	0.0	2.0	0.0	0.0
NKGN NKGen Biotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SRNE Sorrento Therapeutics	0.7104 of 5 stars	0.0	2.0	0.0	4.3	0.0	0.0	0.0
UPTD TradeUP Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIM AIM ImmunoTech	3.00	Buy	$275.00	10,988.71% Upside
NKGN NKGen Biotech	0.00	N/A	N/A	N/A
SRNE Sorrento Therapeutics	0.00	N/A	N/A	N/A
UPTD TradeUP Acquisition	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIM AIM ImmunoTech	$121K	15.66	N/A	N/A	$0.20 per share	12.40
NKGN NKGen Biotech	N/A	N/A	N/A	N/A	($2.68) per share	N/A
SRNE Sorrento Therapeutics	$60.32M	0.04	N/A	N/A	N/A	∞
UPTD TradeUP Acquisition	N/A	N/A	N/A	N/A	($1.59) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIM AIM ImmunoTech	-$28.96M	-$24.68	N/A	N/A	N/A	-12,594.21%	-421.73%	-147.54%	N/A
NKGN NKGen Biotech	-$82.94M	-$2.45	N/A	∞	N/A	N/A	N/A	-479.36%	N/A
SRNE Sorrento Therapeutics	-$572.84M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
UPTD TradeUP Acquisition	-$1M	N/A	0.00	∞	N/A	N/A	N/A	-3.38%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIM AIM ImmunoTech	N/A	N/A	N/A	N/A	N/A
NKGN NKGen Biotech	N/A	N/A	N/A	N/A	N/A
SRNE Sorrento Therapeutics	N/A	N/A	N/A	N/A	N/A
UPTD TradeUP Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIM AIM ImmunoTech	0.05	0.75	0.75
NKGN NKGen Biotech	N/A	0.02	0.02
SRNE Sorrento Therapeutics	N/A	N/A	N/A
UPTD TradeUP Acquisition	N/A	0.09	0.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIM AIM ImmunoTech	12.02%
NKGN NKGen Biotech	76.17%
SRNE Sorrento Therapeutics	0.02%
UPTD TradeUP Acquisition	34.95%

Insider Ownership

Company	Insider Ownership
AIM AIM ImmunoTech	0.02%
NKGN NKGen Biotech	10.36%
SRNE Sorrento Therapeutics	2.60%
UPTD TradeUP Acquisition	55.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIM AIM ImmunoTech	20	764,000	68.74 million	Not Optionable
NKGN NKGen Biotech	N/A	44.95 million	40.29 million	Not Optionable
SRNE Sorrento Therapeutics	800	551.28 million	536.95 million	No Data
UPTD TradeUP Acquisition	2,021	2.17 million	973,000	Not Optionable

UPTD, NKGN, AIM, and SRNE Headlines

Recent News About These Companies

Estrella Immunopharma stock plunges in market debut after SPAC merger

October 2, 2023 | msn.com

SPAC TradeUp, Estrella Biopharma complete merger; shares to debut Oct. 2

September 29, 2023 | msn.com

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

September 29, 2023 | finance.yahoo.com

TradeUP (UPTD) Stock is Up: What's Going On?

September 21, 2023 | benzinga.com

TradeUp (NASDAQ: UPTD) up 67% - Hey, maybe a deal really will be done here

September 15, 2023 | dhakatribune.comD

Why TradeUP Acquisition (UPTD) Stock Is Rocketing Higher

September 1, 2023 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

UPTD, NKGN, AIM, and SRNE Company Descriptions

AIM ImmunoTech NYSE:AIM

$2.48 -0.03 (-1.20%)

Closing price 04:00 PM Eastern

Extended Trading

$2.53 +0.05 (+2.02%)

As of 05:44 PM Eastern

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

NKGen Biotech NYSE:NKGN

$0.13 0.00 (0.00%)

As of 12:37 PM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

Sorrento Therapeutics NASDAQ:SRNE

$0.0048 +0.00 (+118.18%)

As of 03:49 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

TradeUP Acquisition NASDAQ:UPTD

TradeUP Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time